In NSCLC (Non-small cell lung cancer), FDA has approved PD-1 inhibitor in first line setting in patients with high PDL-1 expression (PDL-1 expression >50 %) [14]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.